Details for 2018185835

Up to date per 02.04.2026

Actions

Title / Product Name

KRISTALLINE FORM VON 1-(4-1-(2,6-DIFLUOROBENZYL)-5-DIMETHYLAMINOMETHYL-3-(6-METHOXYPYRIDAZIN-3-YL)-2,4-DIOXO-1,2,3,4-TETRAHYDROTHIENO(2,3-D)-PYRIMIDIN-6YL)PHENYL)-3-METHOXYUREA

Status

Granted/Registered

Protection Type

European Patent

(AT-) Application Number

2018185835

EP Publication Number

3415517

E-Number

1485101

Language

PCT Number

Publication Date

19.12.2018 A

20.04.2022 B1

Registration Date

20.04.2022

AT Publication Date

15.05.2022

Application Date

27.09.2013

Registration Number

Priorities

28.09.2012

2012217679

IPC

C07D 495/04 20060101AFI20201008BHEP

Maximum Duration of Protection

27.09.2033

Owner

Takeda Pharmaceutical Company Limited1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045,JP

Representative

Patentanwalt Mikšovsky KGBisamberger Straße 192100 KorneuburgAT

Inventor

MIWA, KazuhiroTAKEDA PHARMACEUTICAL COMPANY LIMITED 17-85 Jusohonmachi 2-chome Yodogawa-ku Osaka-shi, Osaka 532-0024JP

SASAKI, TsuyoshiTAKEDA PHARMACEUTICAL COMPANY LIMITED 17-85 Jusohonmachi 2-chome Yodogawa-ku Osaka-shi, Osaka 532-0024JP

KOMURA, FumiyaTAKEDA PHARMACEUTICAL COMPANY LIMITED 17-85 Jusohonmachi 2-chome Yodogawa-ku Osaka-shi, Osaka 532-0024JP

Information about Fees